Society for Hematopathology/ European Association for Haematopathology 2013 Workshop Case 145 Nidhi Aggarwal, M.D.; Robert L. Redner, MD; Fiona E. Craig,

Slides:



Advertisements
Similar presentations
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Advertisements

Acute Promyelocytic Leukemia
Approach to Acute Leukemia
MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.
Bibliography University of Pennsylvania Cancer Center. Leukemia U. of Pennsylvania Cancer Center. Feb 12,2009 V3/Leukemia.htmlhttp://
Acute leukemia Mohammed Al-matrafi.
LEUKEMIA—HEMATOLOGY {S1}
Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.
ECSI case Fall 2014 Andrea M. Sheehan, MD Associate Professor of Pathology & Immunology Baylor College of Medicine.
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.
Acute myeloid leukemia: morphology and beyond
ACUTE MYELOID LEUKEMIA Irit Avivi
Hematologic Malignancies
Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.
Chronic lymphocytic leukemia (1)
Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp
NYU Medicine Grand Rounds Clinical Vignette Maryann Kwa, MD PGY-2 January 12, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Acute Myeloid Leukemia
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
Final Results From a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Sekeres MA.
Acute promyelocytic leukemia (APL) From the worst to the best prognosis MUDr. Petr Pavlíček Internal Hematological Clinics FNKV and 3LF UK in Prague.
MOLECULAR GENETICS and LEUKEMIA Clive S. Zent M.D. Division of Hematology/Oncology.
ICCS e-Newsletter CSI Fall 2010 David D. Grier, M.D. Department of Pathology. Wake Forest University.
Blood Cancers in older adults Cancer and Older Adults 19 November 2015 Matthew Foster, MD Assistant Professor of Medicine Leukemia, Lymphoma and Myeloma.
Pei Lin Professor of Pathology Department of Hematopathology
Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
Acute Leukemia Kristine Krafts, M.D..
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Therapeutic Advances in Acute Myleoid Leukemia J Clin Oncol 29: (Volume 29. Number 5. February ) Samuel Aparicio, B.M., B.Ch., Ph.D., and.
P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.
Society for Hematopathology/ European Association for Haematopathology Case 211 Rachel Ochs, MD Adam Bagg, MD Hospital of the University of Pennsylvania.
CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
Acute Leukemia Kristine Krafts, M.D..
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
Session 7, case 171 Extramedullary Manifestations of Myeloid Neoplasms
eCSI case 2 – November 2016 Jyotinder Nain Punia, MD
Acute Myeloid Leukemia
Julia Geyer and Attilio Orazi
Clinically useful prognostic factors in acute myeloid leukemia
Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.
Early T-Cell Precursor ALL in 5 Year Old Female
Leukemia Case 1.
by Michele Paessler, and John Choi
Acute Myeloid Leukemia
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
Diagnostic Hematology
Leukemia.
Mutational Testing to Select Novel Targeted Therapies in AML
Pollyea DA et al. Proc ASCO 2011;Abstract 6505.
Leukemia case (18).
Case study A 36-year-old woman presented with a two-month history of increasing fatigue and abdominal fullness with accompanying loss of appetite. There.
Neoplastic disorder.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
Acute Megakaryocytic Leukemia
Presentation transcript:

Society for Hematopathology/ European Association for Haematopathology 2013 Workshop Case 145 Nidhi Aggarwal, M.D.; Robert L. Redner, MD; Fiona E. Craig, M.D. University of Pittsburgh Medical Center

Clinical History 73 year-old male with history of a high-grade sarcoma of the thigh diagnosed January 2012, status post chemotherapy [Adjuvant Adriamycin (Doxorubicin) and Ifosfamide). Acute myeloid leukemia diagnosed November Enrolled in phase 1 trial ATRA plus Dasatinib (UPCI ). Bone marrow obtained day 28 status post chemotherapy.

Peripheral smear Patient valueReference range WBC0.5X10^9/l Hemoglobin9.7g/dl Platelet9X10^9/l Polys16% (0.08X10^9/l) Lymphocytes82% (0.41X10^9/l) Monocytes2% (0.01X10^9/l)

Bone marrow aspirate: 84% blasts

CD14 - CD36,CD64 + CD15,CD33 + HLA-DR + CD117 - CD34 - SSC CD4 + MPO +

Butyrate esteraseButyrate esterase with fluoride

t(8;16)(p11;p13)

Bone marrow biopsy day 28 status post therapy Bone marrow biopsy at the start of therapy

SH/ EAHP Case 145: Persistent therapy-related AML with t(8;16) (p11;p13). Receiving novel therapy (protocol UPCI ) with ATRA and escalating doses of Dasatinib Started on Decitabine therapy on 01/28/2013 The patient died on 03/11/2013. Follow-up:

AML with t(8;16) (p11;p13) Rare distinct subtype of AML (<1% of all AML). Atlas of Genetic and Cytogenetics in Oncology and Haematology Translocation inhibits RUNX1 regulated transcription, leading to differentiation block. Chr 8: MYST3/ MOZ Chr 16: CERBBP/ CBP

Younger patients including infants More common in women (?) More frequent in therapy related AML than de novo AML – Short latency (6-23months) – Absence of preceding MDS Extramedullary disease especially skin – may precede bone marrow involvement. Relatively high rate of DIC Extremely poor prognosis – Disease free survival very short ~3-4 months & overall survival 8-9 months – Rare spontaneous remission in infants AML with t(8;16) - Clinical features

AML with t(8;16) - Pathologic features Monocytoid/ myelomonocytoid differentiation Morphologic features can overlap with Acute promyelocytic leukemia Erythrophagocytosis Immunophenotype shows myeloid and monocytic markers, and usually CD34 negative and CD117 negative A few known collaborating somatic genetic alterations. J Clin Oncol (1993)11: ; Leukemia Research (2013) 37:32-36; Leukemia (2009) 23:934–943

ATRA classically used to induce differentiation in APL EGFR inhibitors (Erlotinib/ Gefitinib) combined with naturally occurring pro-differentiation agents (ATRA or Vitamin D) helps differentiation of AML [Cell Cycle. 2013;(12):18]. Epigenetic modification [Clin Epigenetics. 2013;5(1):12] – Histone deacetylase inhibitor: Valproic acid – DNA methylation inhibitors Furazolidone has been investigated as a differentiation agent for AML [PLoS One. 2013;8(8):e doi: / journal.pone eCollection 2013]. Therapeutic induction of differentiation.

Patient with AML-M5CD11b: Marker for differentiation Induction of differentiation with ATRA & Dasatinib Src family kinase (SFK), overexpressed in AML, is a negative regulator of ATRA-induced differentiation Dasatinib inhibits ABL and Src family kinase (SFK)

UPCI protocol: Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients with Acute Myeloid Leukemia (AML) Non induction candidate elderly male (>65yrs). Relapsed/Refractory AML: – Failed 2 inductions, or relapsed within 6months. If relapse after >6 months - failed 2 inductions. – AML after MDS/MPN and after chemotherapy also considered). Fixed dose ATRA with escalating doses of Dasatinib.

Diagnosis Proposed Diagnosis – Persistent acute myeloid leukemia with monocytic differentiation and t(8;16), likely therapy related. Consensus Diagnosis – Therapy-related myeloid leukemia, acute myeloid leukemia (monocytic) with t(8;16)(p11;p13)